Trials / Unknown
UnknownNCT04154709
CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Kai Lin Xu; Jun Nian Zheng · Academic / Other
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
Detailed description
This study is indicated for r/r CD19+ B-ALL, the selection of dose levels and the number of subjects are based on clinical trial of similar foreign product, whose primary objective was to explore the safety, main consideration was dose-related safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CTA101 | Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. |
Timeline
- Start date
- 2019-12-10
- Primary completion
- 2021-11-01
- Completion
- 2022-06-01
- First posted
- 2019-11-06
- Last updated
- 2020-01-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04154709. Inclusion in this directory is not an endorsement.